This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jiao, Y. Articles by Maincent, P. Search for Related Content PubMed PubMed Citation Articles by Jiao, Y. Articles by Maincent, P. Related Collections Cardiovascular Pharmacology Heparin

(Circulation. 2002;105:230.)
© 2002 American Heart Association, Inc.

Basic Science Reports

In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits

Yuyan Jiao, PhD; Nathalie Ubrich, PhD; Monique Marchand-Arvier, PhD; Claude Vigneron, PhD; Maurice Hoffman, PhD; Thomas Lecompte, MD; Philippe Maincent, PhD

From the Laboratoire de Pharmacie Galénique (Y.J., N.U., M.H., P.M.), Faculté de Pharmacie, Nancy, and Service d’ Hématologie Biologique (M.M.-A., C.V., T.L.) CHU Brabois, Vandoeuvre-lès-Nancy, France.

Correspondence to Nathalie Ubrich PhD, Laboratoire de Pharmacie Galénique, Faculté de Pharmacie, 5, rue Albert Lebrun, BP 403, 54001 Nancy Cedex, France. E-mail ubrich{at}pharma.u-nancy.fr

Background— Owing to its short half-life and lack of oral absorption, heparin has to be administered by the parenteral route. An oral heparin formulation, however, would avoid the disadvantages of parenteral injections and would consequently be highly desirable for patients. Polymeric nanoparticles (NPs) prepared with biodegradable poly--caprolactone (PCL) and poly(lactic-co-glycolic acid) (PLGA) and nonbiodegradable positively charged polymers (Eudragit RS and RL), used alone or in combination, were evaluated in vitro and in vivo after a single oral administration of heparin-loaded NPs in rabbits.

Methods and Results— After oral administration of heparin-loaded NPs in rabbits (600 IU/kg), increases in both anti–factor Xa activity and activated partial thromboplastin time (aPTT) were detected with each formulation. Moreover, the anti-Xa activity was detected for a longer period than when a heparin solution was administered intravenously. A peak concentration of 0.16±0.01 IU/mL and an average aPTT of 24 seconds (2-fold increase) were obtained 7 hours after oral dosing of Eudragit RL/PCL NPs containing heparin, exhibiting an absolute bioavailability of 23%.

Conclusions— The significant increases in anti–factor Xa activity and aPTT confirmed the oral absorption in rabbits of heparin released from polymeric NPs.

Key Words: heparin • anticoagulants • drugs • nanoparticles

This article has been cited by other articles:

				H. Dou, C. J. Destache, J. R. Morehead, R. L. Mosley, M. D. Boska, J. Kingsley, S. Gorantla, L. Poluektova, J. A. Nelson, M. Chaubal, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery Blood, October 15, 2006; 108(8): 2827 - 2835. [Abstract] [Full Text] [PDF]

				P R Sinnaeve and F J Van de Werf Will oral antithrombin agents replace warfarin? Heart, August 1, 2004; 90(8): 827 - 828. [Abstract] [Full Text] [PDF]